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ABSTRACT
Introduction synapse dysfunction is emerging as an 
early pathological event in frontotemporal dementia 
(FTD), however biomarkers are lacking. We aimed 
to investigate the value of cerebrospinal fluid (csF) 
neuronal pentraxins (nPTXs), a family of proteins 
involved in homeostatic synapse plasticity, as novel 
biomarkers in genetic FTD.
Methods We included 106 presymptomatic and 
54 symptomatic carriers of a pathogenic mutation in 
GRN, C9orf72 or MAPT, and 70 healthy non- carriers 
participating in the genetic Frontotemporal dementia 
initiative (genFi), all of whom had at least one csF 
sample. We measured csF concentrations of nPTX2 
using an in- house elisa, and nPTX1 and nPTX receptor 
(nPTXr) by Western blot. We correlated nPTX2 with 
corresponding clinical and neuroimaging datasets as well 
as with csF neurofilament light chain (nfl) using linear 
regression analyses.
Results symptomatic mutation carriers had lower 
nPTX2 concentrations (median 643 pg/ml, iQr 
(301–872)) than presymptomatic carriers (1003 pg/
ml (624–1358), p<0.001) and non- carriers (990 pg/ml 
(597–1373), p<0.001) (corrected for age). similar results 
were found for nPTX1 and nPTXr. among mutation 
carriers, nPTX2 concentration correlated with several 
clinical disease severity measures, nfl and grey matter 
volume of the frontal, temporal and parietal lobes, insula 
and whole brain. nPTX2 predicted subsequent decline 
in phonemic verbal fluency and clinical Dementia rating 
scale plus FTD modules. in longitudinal csF samples, 
available in 13 subjects, nPTX2 decreased around 
symptom onset and in the symptomatic stage.
Discussion We conclude that nPTX2 is a promising 
synapse- derived disease progression biomarker in 
genetic FTD.
INTRoDuCTIoN
Frontotemporal dementia (FTD), a common form 
of early- onset dementia, has an autosomal dominant 
inheritance in 20%–30% of patients, most often 
due to mutations in granulin (GRN), chromosome 
9 open reading frame 72 (C9orf72) or microtubule- 
associated protein tau (MAPT).1 Developing sensi-
tive biomarkers to detect disease onset at an early, 
even preclinical stage is of utmost importance for 
upcoming therapeutic interventions. Genetic forms 
of FTD provide a unique opportunity to study 
disease progression from presymptomatic to overt 
FTD and to identify novel biomarkers.
Our previous proteomics study identified 
neuronal pentraxin receptor (NPTXR) in cerebro-
spinal fluid (CSF) as the most promising candidate 
biomarker in genetic FTD, with markedly reduced 
levels in the symptomatic stage.2 NPTXR forms 
complexes with NPTX1 and NPTX2 (also termed 
neuronal activity related protein, Narp) at excit-
atory synapses of pyramidal neurons onto parval-
bumin interneurons and contributes to synaptic 
homeostatic plasticity.3 4 Increasing evidence 
suggests that dysfunction and degeneration of 
synapses is an early pathological event in FTD,5–7 
especially in GRN- associated FTD,8–10 a concept 
widely recognised in other neurodegenerative 
diseases.5 11 Fluid biomarkers reflecting synaptic 
integrity in FTD might therefore contribute to an 
early diagnosis and monitoring of disease progres-
sion in clinical practice and clinical trials. Following 
studies in Alzheimer’s disease (AD) that identified 
NPTXs as candidate biomarkers,12–20 we hypothe-
sised that NPTXs could be valuable synapse- derived 
biomarkers in genetic FTD.
In the present study, we measured CSF NPTXs 
in a large cohort of GRN, C9orf72 and MAPT 
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mutation carriers participating in the international Genetic FTD 
Initiative (GENFI). We focused our attention on NPTX2, as the 
available ELISA for NPTX2 allowed for more accurate quan-
titative measurements than the Western blots used for NPTX1 
and NPTXR. We explored the relationship between NPTX2 and 
clinical disease severity, grey matter volume and CSF neurofila-
ment light chain (NfL), a marker of neuroaxonal damage.21
MeThoDS
Subjects
Subjects were included from 16 centres across Europe and Canada 
participating in GENFI, a longitudinal cohort study of patients 
with FTD due to a pathogenic mutation in GRN, C9orf72 or 
MAPT and healthy 50% at- risk relatives (either presymptomatic 
mutation carriers or non- carriers). Participants underwent an 
annual assessment as previously described,22 including neuro-
logical and neuropsychological examination, MRI of the brain, 
and collection of blood and CSF. Knowledgeable informants 
completed questionnaires about potential changes in cognition 
or behaviour.
For the present study, we included all participants with at 
least one CSF sample, amounting to 54 symptomatic mutation 
carriers (15 GRN, 31 C9orf72, 8 MAPT), 106 presymptomatic 
mutation carriers (47 GRN, 42 C9orf72, 17 MAPT) and 70 non- 
carriers. Longitudinal CSF samples were available in 13 subjects.
Mutation carriers were considered symptomatic if they fulfilled 
international consensus criteria for FTD.23 24 Furthermore, as 
C9orf72 mutations are also associated with amyotrophic lateral 
sclerosis (ALS), which is increasingly considered part of the FTD 
disease spectrum,1 C9orf72 mutation carriers fulfilling criteria 
for ALS,25 but not FTD, were also considered symptomatic. We 
calculated disease duration based on a caregiver’s estimation of 
the emergence of first symptoms.
Global cognition was scored using the Mini Mental State Exam-
ination (MMSE) and Clinical Dementia Rating scale (CDR) plus 
FTD modules.26 The Revised Cambridge Behavioural Inventory 
(CBI- R) was used to measure behavioural changes.27 The Trail 
Making Test part B (TMT- B) and phonemic verbal fluency were 
included as measures of executive functioning.28 TMT- B was 
truncated to 300 s for subjects that exceeded the time limit. All 
scores were collected within 6 months of CSF collection.
T1- weighted MRI on three Tesla scanners was obtained within 
6 months of CSF collection in 190 participants (35 symptomatic 
and 91 presymptomatic mutation carriers, 64 non- carriers). All 
MRI scans were acquired using a standardised GENFI protocol.22 
T1- weighted volumetric MRI scans were parcellated into brain 
regions as previously described,22 using an atlas propagation and 
fusion strategy29 to generate volumes of the whole brain, frontal, 
temporal, parietal and occipital lobes, insula and cingulate gyrus. 
Brain volumes were expressed as a percentage of total intracra-
nial volume (TIV), computed with SPM12 running under Matlab 
R2014b (Math Works, Natick, Massachusetts, USA).30
Sample collection and laboratory methods
CSF was collected in polypropylene tubes, centrifuged and 
stored at −80°C within 2 hours of withdrawal according to a 
standardised GENFI protocol.
NPTX2 concentrations were measured using an in- house 
ELISA as described previously.12 The intra- assay and interassay 
coefficients of variation (CV) were <2% and<5%, respec-
tively. The lower limit of quantification (LLOQ) was 5 pg/mL; 
all NPTX2 measurements were above the LLOQ. NPTX1 and 
NPTXR were measured by Western blot. Rabbit anti- NPTX1 
was described previously3; sheep anti- NPTXR antibody is from 
R&D systems (Cat. Number: AF4414; RRID: AB_2153869). 
Immunoreactive bands were visualised by the enhanced chemi-
luminescent substrate (ECL, Pierce) on X- ray film and quan-
tified using the image software TINA ( www. tina- vision. net). 
Western blot results were expressed as a percentage of abun-
dancy compared with non- carriers, that is, mean abundancy in 
non- carriers was set at 100%. Detailed methods are reported in 
online supplementary file 1.
All NPTX measurements were performed in two batches in 
the Neuroscience Laboratory at Johns Hopkins University, Balti-
more, USA. The mean CV of NPTX2 of the two batches was 
5.4%. Longitudinal measurements were performed in one batch.
CSF NfL concentrations were measured in duplicate in one 
batch using the Simoa NF- Light Advantage Kit from Quanterix 
on a Simoa HD-1 analyser instrument according to manufactur-
er’s instructions. The mean CV of duplicate measurements was 
3.2% (range 0.1%–15.6%). NfL measurements were missing 
in four subjects (two symptomatic GRN and two symptomatic 
C9orf72 mutation carriers) due to insufficient CSF.
Standard protocol approvals and patient consents
Clinical researchers were blinded to the genetic status of at- risk 
individuals unless they had undergone predictive testing. 
Laboratory technicians were blinded to all clinical and genetic 
information.
Statistical analysis
Statistical analyses were performed in IBM SPSS Statistics V.24 
and R. Graphs were drafted in R and GraphPad Prism 8. Statis-
tical significance was set at 0.05 (two- sided). The primary anal-
ysis in the study was to investigate whether NPTX2, NPTX1 
and NPTXR concentration differ among symptomatic mutation 
carriers, presymptomatic mutation carriers and non- carriers. 
We restricted correlative analyses of clinical and neuroimaging 
parameters to NPTX2 because an ELISA was available, which is 
more sensitive for quantitative analyses than Western blots used 
for NPTX1 and NPTXR.
Demographic and clinical variables were compared between 
groups using Kruskal- Wallis tests for continuous variables and 
a χ2 test for sex. Normality of biomarker data was assessed 
using Kolmogorov- Smirnov tests and visual inspection of Q- Q 
plots. While raw biomarker values were not normally distrib-
uted, normal distributions were achieved after square- root 
transformation of NPTX2 and log- transformation of NfL. We 
performed analyses of covariance (ANCOVAs) on transformed 
biomarker values with age as a covariate to test for group differ-
ences. In comparisons between symptomatic mutation carriers, 
we also included disease duration as a covariate.
The diagnostic performance of NPTX2 to discriminate 
between the three clinical groups (symptomatic mutation 
carriers, presymptomatic mutation carriers, non- carriers) was 
assessed by the area under the curve (AUC) of receiver operating 
characteristic analyses, with optimal cut- off levels determined by 
the highest Youden’s index.31
Linear regression models were constructed to study the rela-
tionship between NPTX2 concentration (dependent variable; 
square- root transformed to meet model assumptions) and (1) 
regional grey matter volume, (2) clinical disease severity measures 
and (3) NfL, with age, gender and study site as covariates. For 
analyses of cognitive tests (MMSE, TMT- B, phonemic verbal 
fluency) we also included years of education as a covariate. All 
analyses were performed for mutation carriers combined and for 
Protected by copyright.
 o
n
 June 25, 2020 at Universita degli Studi di M
ilano.
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-322493 on 9 April 2020. Downloaded from 
614 van der ende el, et al. J Neurol Neurosurg Psychiatry 2020;91:612–621. doi:10.1136/jnnp-2019-322493
Neurodegeneration
Table 1 Subject characteristics. The clinical phenotype of symptomatic mutation carriers was behavioural variant FTD (n=37), primary progressive 
aphasia (n=7), FTD with amyotrophic lateral sclerosis (ALS) (n=4), ALS without FTD (n=3), memory- predominant FTD (n=1), progressive supranuclear 
palsy (n=1) and dementia not otherwise specified (n=1). Continuous variables are reported as medians±IQR
Non- carriers Presymptomatic carriers Symptomatic carriers P value
N 70 106 54 –
Sex, male (%) 31 (44%) 47 (44%) 32 (59%) 0.157*
Age at CSF collection, years 47 (40–58) 45 (34–56) 63 (56–69) <0.001†
MMSE 30 (29–30) 30 (29–30) 26 (24–28) <0.001†
CDR plus FTD modules 0 (0–0) 0 (0–0) 9 (3–10) <0.001†
Disease duration, years – – 3 (2–6) –
NPTX2, pg/mL 990 (597–1373) 1003 (624–1358) 643 (301–872) <0.001‡
Gene- specific information GRN C9orf72 MAPT GRN C9orf72 MAPT P value
N 47 42 17 15 31 8 –
Age at CSF collection, years 54 (41–58) 43 (32–53) 42 (34–46) 64 (61–69) 60 (55–70) 61 (53–64) <0.001†
NPTX2, pg/mL 1072 (661–1406) 901 (534–1387) 1079 (389–1263) 741 (385–870) 609 (305–884) 561 (233–861) <0.001‡
Age at symptom onset, years – – – 63 (54–66) 55 (49–62) 55 (52–58) 0.109†
Disease duration, years – – – 2 (1–4) 4 (2–8) 3 (1–8) 0.238†
*χ2 test.
†Kruskall- Wallis tests.
‡ANCOVA with age as covariate.
ANCOVA, Analysis of covariance; CDR, Clinical Dementia Rating scale; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; MMSE, Mini Mental State Examination; NPTX, 
neuronal pentraxin.
symptomatic and presymptomatic mutation carriers separately. 
Correction for multiple comparisons was done with the Bonfer-
roni method.
Additional linear regression models were constructed to test 
whether NPTX2 could predict subsequent cognitive decline, as 
measured by annualised changes in clinical disease severity scores 
(score at the time of CSF collection subtracted from a later score 
and divided by time interval), correcting for age, gender and 
study site and in cognitive tests for years of education.
Due to the limited sample size, statistical analyses on longitu-
dinal NPTX2 measurements were limited to exploratory correla-
tions between changes in NPTX2 and time interval, to test for an 
overall trend in NPTX2 concentration over time.
Data availability
The raw data of this project is part of GENFI and de- identified 
patient data can be accessed on reasonable request ( j. c. vanswi-
eten@ erasmusmc. nl and  j. rohrer@ ucl. ac. uk).
ReSulTS
Demographic and clinical data
Subject characteristics are shown in table 1. Symptomatic 
mutation carriers were significantly older than presymptom-
atic carriers and non- carriers, both overall and for each genetic 
group (GRN, C9orf72 and MAPT) separately. Three presymp-
tomatic mutation carriers converted to the symptomatic stage 
(‘converters’) during follow- up (2 GRN, 1 MAPT).
NPTX2 concentration
Overall, NPTX2 levels were lower in symptomatic mutation 
carriers (median 643 pg/mL, IQR 301–872) than in presymp-
tomatic carriers (1003 pg/mL (624–1358); p<0.001) and non- 
carriers (990 pg/mL (597–1373); p<0.001) (figure 1A). NPTX2 
levels did not differ significantly between presymptomatic muta-
tion carriers and non- carriers (p=0.859).
When analysed per genetic group, symptomatic GRN and 
C9orf72 mutation carriers had significantly lower NPTX2 
levels than their presymptomatic counterparts (GRN: 741 pg/
mL vs 1072 pg/mL; p=0.003; C9orf72: 609 pg/mL vs 901 pg/
mL; p=0.023) and non- carriers (GRN: p=0.007; C9orf72: 
p=0.004) (table 1, figure 1B). Symptomatic MAPT mutation 
carriers had lower NPTX2 levels than non- carriers (561 pg/mL; 
p=0.027) but not compared with presymptomatic MAPT muta-
tion carriers (1079 pg/mL; p=0.213). NPTX2 levels did not 
differ between symptomatic carriers of different genetic groups 
(p=0.709). Similar results were obtained after excluding muta-
tion carriers with ALS without FTD (n=3).
Overall, a correlation was found between NPTX2 and 
age (rs=−0.141; p=0.033) (online supplementary figure 
1); this correlation was also found in mutation carriers alone 
(rs=−0.205; p=0.009) but not in non- carriers alone (rs=0.070; 
p=0.566). NPTX2 levels did not differ by sex (p=0.976).
Diagnostic accuracy of NPTX2
The AUC for NPTX2 to distinguish symptomatic from presymp-
tomatic mutation carriers was 0.71 (95% CI 0.63 to 0.80), with 
an optimal cut- off of 895 pg/mL (sensitivity 82%, specificity 
56%) (online supplementary figure 2). The AUC to distinguish 
symptomatic mutation carriers from non- carriers was 0.71 
(95% CI 0.61 to 0.80), with an optimal cut- off of 945 pg/mL 
(sensitivity 83%, specificity 53%). NPTX2 did not distinguish 
presymptomatic mutation carriers from non- carriers (AUC 0.50 
(95% CI 0.41 to 0.58)).
NPTX2 and clinical and neuroimaging data
NPTX2 levels in mutation carriers correlated significantly with 
grey matter volume of the whole brain, frontal, temporal and 
parietal lobes and insula, and in symptomatic mutation carriers 
alone, with whole brain volume, frontal lobe and insular 
volume (figure 2A,B, table 2, online supplementary figure 3). In 
presymptomatic mutation carriers, NPTX2 levels were associ-
ated with frontal lobe volume but this was no longer significant 
after multiple testing correction (table 2). Among non- carriers 
(n=64), no significant associations were found with any of the 
regional grey matter volumes (online supplementary table 1). 
Protected by copyright.
 o
n
 June 25, 2020 at Universita degli Studi di M
ilano.
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-322493 on 9 April 2020. Downloaded from 
615van der ende el, et al. J Neurol Neurosurg Psychiatry 2020;91:612–621. doi:10.1136/jnnp-2019-322493
Neurodegeneration
Figure 1 nPTX2 levels (a) in presymptomatic (n=106) and symptomatic 
mutation carriers (n=54) and non- carriers (n=70) and (B) separated by 
genetic group. Whiskers indicate minimum and maximum values. Orange 
squares indicate subjects who converted to the symptomatic stage 
during follow- up (n=3); grey asterisks indicate subjects with amyotrophic 
lateral sclerosis (als) without frontotemporal dementia (FTD) (n=3); grey 
crosses indicate subjects with both FTD and als (n=4). P values are from 
analyses of covariance (ancOVas) with age as a covariate and Bonferroni 
correction for multiple comparisons. *p<0.05; **p<0.01; ***p<0.001. 
csF, cerebrospinal fluid; nPTX, neuronal pentraxin; Pre, presymptomatic 
mutation carrier; sYM: symptomatic mutation carrier.
Results were unchanged after repeating the analyses with raw 
grey matter volumes (ie, not corrected for TIV).
Among mutation carriers, NPTX2 levels correlated with 
MMSE, TMT- B, phonemic verbal fluency, CDR plus FTD 
modules and CBI- R (table 3, figure 2C,D). In symptomatic 
mutation carriers alone, these correlations were similarly present 
for MMSE, TMT- B, CDR plus FTD modules and CBI- R. In 
presymptomatic mutation carriers alone, an association was 
found for TMT- B, which was no longer statistically significant 
after correction for multiple testing (table 3).
NPTX2 and NFl concentration
Symptomatic mutation carriers had significantly higher NfL 
levels than presymptomatic carriers (2575 pg/mL (1218–4592) 
vs 471 pg/mL (305–729); p<0.001) and non- carriers (421 pg/
mL (298–555); p<0.001). These differences were also found 
for each genetic group separately (online supplementary figure 
4). No differences were seen between presymptomatic muta-
tion carriers and non- carriers (p=0.517). Similar results were 
obtained after exclusion of nine outliers (values>3*IQR from 
the median) and after exclusion of subjects with ALS without 
FTD (n=3).
NPTX2 concentration across all mutation carriers was 
inversely associated with NfL concentration (b=−5.69E-4; 
p=0.010; n=156) (figure 3). This correlation was not observed 
for symptomatic (b=−3.61E-4; p=0.141; n=50) or presymp-
tomatic mutation carriers (b=−3.64E-5; p=0.971; n=106) 
alone. Repeating the analyses for symptomatic mutation carriers 
after exclusion of patients with concomitant or isolated ALS 
revealed a trend towards association between NfL and NPTX2 
(b=−7.55E-4; p=0.061; n=43).
longitudinal NPTX2 measurements
Longitudinal CSF samples were available in 10 presymptomatic 
mutation carriers (of whom two had converted to the symptom-
atic stage at follow- up CSF collection), two symptomatic muta-
tion carriers and one non- carrier. The median time between 
samples was 2.0 years (IQR 1.8–2.1).
In the MAPT converter, visually, a decrease in NPTX2 was 
observed in two presymptomatic samples, with a further decrease 
in the symptomatic sample (figure 4). In the GRN converter, 
NPTX2 was already below the proposed cut- off level 1.2 years 
before symptom onset, with a further decrease in the symptom-
atic sample. Both symptomatic mutation carriers demonstrated 
NPTX2 decreases over time. Lower NPTX2 levels at follow- up 
were observed in all presymptomatic mutation carriers over 
the age of 50 years, while in younger presymptomatic carriers, 
NPTX2 trajectories seemed to be more varied. NPTX2 in one 
non- carrier subject was visually stable (figure 4).
There was no correlation between change in NPTX2 levels and 
time interval between CSF collections (rs=−0.116; p=0.705) 
(online supplementary figure 5).
NPTX2 and subsequent cognitive decline
NPTX2 was significantly associated with annualised change in 
phonemic verbal fluency (b=0.004; p=0.001; n=118), and 
CDR plus FTD modules (b=−0.001; p=0.025; n=105). The 
former remained significant after adjusting for clinical status, 
frontal lobe volume and CSF NfL. A trend was found for annu-
alised change in MMSE (b=0.001; p=0.077; n=136). NPTX2 
level was not associated with annualised change in CBI- R 
(p=0.200; n=93) or TMT- B (p=0.693; n=107) (online supple-
mentary table 2, figure 6).
NPTX1 and NPTXR concentration
NPTX1 levels were significantly lower in symptomatic muta-
tion carriers compared with presymptomatic carriers (median 
54% (36–88) vs 86% (55–118); p<0.001) and non- carriers 
(92% (61–123); p<0.001). Similar results were found for 
NPTXR (symptomatic vs presymptomatic: 51% (27–85) vs 81% 
(51–147); p=0.002; symptomatic vs non- carriers: 51% vs 76% 
(51–133); p<0.001) (figure 5). Separated by genetic group, 
symptomatic C9orf72 and MAPT mutation carriers had signifi-
cantly lower NPTX1 and NPTXR levels than non- carriers. In 
GRN mutation carriers, a similar pattern was observed, although 
not statistically significant. NPTX1 and NPTXR levels were 
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Figure 2 relationship between nPTX2 and (a) frontal lobe volume (n=126), (B) insular volume (n=126), (c) Mini Mental state examination (MMse) 
(n=145) and (D) clinical Dementia rating scale (cDr) plus FTD modules (n=120) among mutation carriers. b and p were obtained through multiple linear 
regression with square- root transformed nPTX2 as the dependent variable, adjusting for age, gender and study site; for MMse, we also included years of 
education as a covariate. csF, cerebrospinal fluid; FTD, frontotemporal dementia; nPTX, neuronal pentraxin; TiV, total intracranial volume.
strongly correlated with NPTX2 (rs=0.828 and rs=0.850, 
respectively, both p<0.001) (online supplementary figure 7).
DISCuSSIoN
The present study of a large international cohort of genetic 
FTD reports low levels of NPTX2, NPTX1 and NPTXR in the 
symptomatic stage, with correlations between NPTX2 and both 
disease severity and grey matter volume. We propose NPTX2 
as a novel synapse- derived biomarker of disease progression in 
genetic FTD.
The decreased levels of CSF NPTXs in patients with GRN- 
associated, C9orf72- associated and MAPT- associated FTD prob-
ably reflect a loss or dysfunction of their synaptic sources.32 
Complexes of NPTXs accumulate at excitatory synapses between 
glutamatergic pyramidal neurons and parvalbumin- expressing 
(PV) interneurons in the cerebral cortex, hippocampus and cere-
bellum.32 NPTXs modulate the strength of these synapses through 
recruitment of AMPA- type glutamate receptors (AMPARs) to the 
postsynaptic membrane, thereby regulating excitatory drive of 
pyramidal neurons onto PV- interneurons.4 12 32 PV- interneurons 
in turn contact surrounding pyramidal neurons and prevent 
neural circuits from becoming too active (diagram provided in 
Hanson33).34 The expression of NPTX2—but not NPTX1 or 
NPTXR—is induced by synapse activity,3 35 and the relative ratio 
of the NPTXs in the complex is dynamically dependent on the 
neuron’s activity. Of the three proteins, NPTX2 is most effective 
at AMPAR recruitment, but their combined expression is syner-
gistic.3 NPTX2 knockout mice have reduced AMPARs, resulting 
in less inhibitory PV- interneuron activity; the subsequent disrup-
tion of pyramidal neuron—PV- interneuron circuits is thought 
to underlie cognitive impairment, and NPTX2 loss has been 
hypothesised to drive neurodegeneration.12 Restoring these 
circuits is emerging as a potential treatment strategy in neuro-
degenerative disease36; in this regard, measuring NPTX2 in CSF 
could be especially relevant to select and monitor patients with 
aberrant pyramidal neuron- PV interneuron circuits.12 36 The 
lack of correlation in the current study between NPTX2 and 
brain volume in healthy non- carriers reflects that NPTX2 is not 
merely a measure of synapse density.
The present study reports low NPTX2 levels in all included 
forms of genetic FTD. The lack of significant differences between 
presymptomatic and symptomatic MAPT mutation carriers likely 
reflects insufficient statistical power given the small sample size, 
or could reflect differences in underlying pathology (eg, tau 
pathology in MAPT- associated FTD vs TDP-43 pathology in 
GRN- associated and C9orf72- associated FTD).1 While these 
findings are novel in FTD, a few studies have identified reduced 
NPTXs in AD, both in brain and in CSF,12–19 although mostly 
through mass spectrometry approaches (box 1). The observed 
reductions in both FTD and AD suggest that reduced NPTXs 
reflect general rather than gene- specific or disease- specific 
pathological alterations. To date, CSF NPTX2 levels in other 
neurodegenerative diseases have not been reported; future 
research should focus on the measurement of CSF NPTXs 
across a broader range of neurodegenerative diseases, including 
sporadic FTD and Parkinson’s disease.37
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Table 2 Relationship between NPTX2 and grey matter volume. 
Results were obtained through multiple linear regression with square- 
root transformed NPTX2 as dependent variable, adjusting for age, 
gender and study site. All grey matter volumes were corrected for total 
intracranial volume
All mutation carriers 
(n=126)
Symptomatic 
mutation carriers 
(n=35)
Presymptomatic 
mutation carriers 
(n=91)
Whole brain volume
  b (SE) 1.07 (0.25) 1.21 (0.42) 0.58 (0.39)
  β 0.533 0.585 0.215
  p <0.001* 0.007* 0.145
Frontal lobe
  b (SE) 3.86 (0.83) 4.40 (1.33) 3.48 (1.44)
  β 0.516 0.623 0.331
  p <0.001* 0.003* 0.018
Temporal lobe
  b (SE) 4.01 (1.32) 5.00 (2.27) 0.67 (2.11)
  β 0.338 0.448 0.039
  p 0.003* 0.037 0.752
Parietal lobe
  b (SE) 4.89 (1.77) 5.51 (4.25) 2.70 (2.18)
  β 0.323 0.319 0.169
  p 0.007* 0.208 0.218
Occipital lobe
  b (SE) 1. 45 (1.77) -6.65 (4.03) 3.10 (1.97)
  β 0.086 -0.341 0.185
  p 0.412 0.112 0.119
Cingulate gyrus
  b (SE) 10.49 (5.27) 14.72 (11.32) 0.46 (7.27)
  β 0.205 0.285 0.008
  p 0.049 0.206 0.95
Insula
  b (SE) 37.22 (8.69) 69.21 (13.09) 12.61 (13.16)
  β 0.482 0.786 0.119
  p <0.001* <0.001* 0.341
P values marked with an asterisk remained significant after Bonferroni correction. b 
indicates unstandardised regression coefficient. β indicates standardised regression 
coefficient.
NTPX, neuronal pentraxin.
Table 3 Relationship between NPTX2 and disease severity scores, 
obtained through multiple linear regression with square- root 
transformed NPTX2 as dependent variable, adjusting for age, gender, 
study site and, in analyses of MMSE, TMT- B and letter fluency, years of 
education
All mutation 
carriers
Symptomatic 
mutation carriers
Presymptomatic 
mutation carriers
MMSE
  n 145 50 95
  b (SE) 1.21 (0.26) 0.98 (0.29) 1.58 (0.79)
  β 0.442 0.467 0.23
  p <0.001* 0.002* 0.051
TMT- B
  n 125 34 91
  b (SE) −0.04 (0.01) −0.02 (0.02) −0.09 (0.04)
  β −0.353 −0.234 −0.259
  p <0.001* <0.001* 0.03
Phonemic verbal fluency
  n 132 39 93
  b (SE) 0.14 (0.05) 0.15 (0.10) 0.05 (0.08)
  β 0.255 0.25 0.076
  p 0.009* 0.151 0.536
CDR plus FTD modules
  n 120 33 87
  b (SE) −0.85 (0.19) −0.72 (0.24) −1.19 (1.67)
  β −0.435 −0.479 −0.078
  p <0.001* 0.007* 0.478
CBI- R
  n 119 40 79
  b (SE) −0.13 (0.03) −0.10 (0.04) −0.02 (0.14)
  β −0.489 −0.394 −0.014
  p <0.001* 0.017* 0.906
P values are before multiple testing correction; p values marked with an asterisk 
remained significant after Bonferroni correction. b indicates unstandardised 
regression coefficient; β indicates standardised regression coefficient.
CBI- R, Revised Cambridge Behavioural Inventory; CDR, Clinical Dementia Rating 
scale; MMSE, Mini Mental State Examination; TMT- B, Trail Making Test part B.
Figure 3 correlation between nPTX2 and nfl levels in presymptomatic 
(n=106) and symptomatic (n=50) mutation carriers. nfl is plotted on a log- 
scale for visualisation purposes. b and p were obtained through multiple 
linear regression with square- root transformed nPTX2 as the dependent 
variable, adjusting for age, gender and study site. csF, cerebrospinal fluid; 
nfl, neurofilament light chain; nPTX, neuronal pentraxin.
The correlations between NPTX2 concentration and several 
disease severity measures suggest that NPTX2 might further 
decrease with disease progression. This is supported by longi-
tudinal NPTX2 decreases over time in two symptomatic 
mutation carriers and could reflect a link between progressive 
synapse pathology and cognitive decline; more longitudinal 
data is needed to confirm this. The association between NPTX2 
levels and subsequent decline in phonemic verbal fluency and 
CDR plus FTD modules indicates that NPTX2 may have prog-
nostic significance and is in line with previous findings in AD. 
The correlations between NPTX2 and grey matter volume in 
regions typically affected in FTD, including the frontal lobe and 
insula,23 are comparable to the previously reported correlations 
with hippocampal volume in AD and provide further evidence 
for NPTX2 as a disease progression marker.12 17
Longitudinally, we observed strong NPTX2 decreases in two 
converters; in the MAPT converter, this decrease was already 
observed in two presymptomatic samples; similarly, in the GRN 
converter, NPTX2 levels were already low in the presymptom-
atic sample. Although these results must be interpreted with 
caution due to the small sample size, they provide tentative 
evidence that NPTX2 might be an early disease marker. The 
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Figure 4 longitudinal nPTX2 levels plotted against age in 13 subjects 
with multiple csF samples. a line is drawn between nPTX2 levels 
of follow- up samples. Presymptomatic samples are shown as green 
squares, symptomatic samples as red triangles and the non- carrier as 
blue circles. GRN mutation carriers are shown as open symbols, C9orf72 
mutation carriers as filled symbols and the MAPT mutation carrier as 
half- filled symbols. Dotted horizontal line indicates median nPTX2 level 
in presymptomatic mutation carriers (1003 pg/ml); dashed horizontal 
line indicates median in symptomatic mutation carriers (644 pg/ml). For 
blinding purposes, a jitter of ±2 years was applied to all subjects. csF, 
cerebrospinal fluid; nPTX, neuronal pentraxin.
Figure 5 nPTX1 and nPTXr levels as measured by Western blot. (a) representative (cropped) Western blots of nPTX1 and nPTXr (n=230); (B, c) nPTX1 
and nPTXr levels across groups, expressed as a percentage of band intensity compared with non- carriers. Whiskers indicate minimum and maximum values. 
Displayed significance levels are from analysis of covariance (ancOVa) on square- root transformed relative band intensities of nPTX1 and nPTXr with age 
as a covariate. *p<0.05; **p<0.01. csF, cerebrospinal fluid; nPTX, neuronal pentraxin; Pre, presymptomatic mutation carrier; sYM, symptomatic mutation 
carrier.
Box 1 CSF NPTXs in other neurodegenerative diseases
 ► Cerebrospinal fluid (CSF) neuronal pentraxin (NPTX)2 levels 
are reduced in patients with Alzheimer’s disease (AD) 
compared with controls.12 14 17 In AD, low CSF NPTX2 levels 
are associated with cognitive impairment and subsequent 
memory decline, as well as hippocampal atrophy and 
subsequent medial temporal lobe atrophy.12 17
 ► To date, CSF NPTX2 levels have not been reported in other 
neurodegenerative diseases, such as sporadic FTD and 
Parkinson’s disease.
 ► Differentially regulated levels of CSF NPTX1 and NPTXR have 
been reported in patients with AD, mostly identified through 
mass spectrometry approaches.13 15 16 18–20 In presymptomatic 
stages of autosomal dominant AD, mild cognitive impairment 
and early- stage AD, a transient increase in NPTXs has been 
observed.15 16 19 20
 ► In brain tissue, NPTX2 levels are decreased in patients with 
AD.12 Conversely, one study has reported accumulation of 
NPTX2 in Lewy bodies in patients with Parkinson’s disease.37
overall lack of differences in NPTXs between presymptomatic 
mutation carriers and non- carriers might reflect the inclusion of 
mutation carriers of all ages; therefore, time to symptom onset 
was highly variable. Remarkably, in presymptomatic autosomal 
dominant AD, mild cognitive impairment and early stage AD, Protected by copyright.
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a transient increase in NPTXs has been observed, with a subse-
quent decline as the disease progresses.15 16 19 20 This discrepancy 
in NPTXs dynamics may result from differences in underlying 
pathophysiology.
The diagnostic accuracy of NPTX2 of 71% to distinguish 
symptomatic from presymptomatic mutation carriers is compa-
rable to that of neurogranin, the most evaluated synapse- derived 
CSF biomarker for AD.38 Its longitudinal evaluation, especially 
in the late- presymptomatic stage, might be more valuable than 
cross- sectional measurements. It is promising that Ma et al39 
observed a correlation between NPTX1 in plasma and brain 
tissue; further studies are warranted to investigate whether 
NPTX2 can also be reliably measured in the blood, which would 
offer opportunities for longitudinal studies with larger numbers 
of samples.
We found an inverse correlation between NPTX2 and 
NfL in mutation carriers. NfL is a sensitive marker of neuro-
axonal degeneration which is elevated in CSF and blood in 
the symptomatic stage of genetic FTD40 and in various other 
neurological disorders.21 Although a trend was found for 
symptomatic carriers alone after exclusion of ALS patients 
(who are known to have very high NfL levels),21 the lack of 
a stronger correlation probably reflects that NPTX2 and NfL 
are markers of different pathological processes which do not 
occur simultaneously.
Strengths of this study include the large sample size, despite 
the relative rarity of the disease, and the availability of corre-
sponding clinical and brain imaging datasets. The inclusion 
of subjects with specific genetic defects allowed us to define 
pathologically homogeneous groups. Our NPTX2 findings are 
supported by similar results in NPTX1 and NPTXR, which 
correlated strongly with NPTX2, and indicate an overall reduc-
tion in NPTXs in genetic FTD.
The findings of this study must be viewed in light of some 
limitations. First, our longitudinal NPTX2 measurements were 
too limited in number to draw strong conclusions and require 
replication and more extensive statistical analyses in larger data-
sets. Second, using diagnostic criteria to label mutation carriers 
as presymptomatic or symptomatic may have failed to recognise 
subjects in a very early symptomatic stage. We calculated disease 
duration based on estimated time of symptom onset, rather than 
diagnosis, to ensure that any diagnostic delay did not affect 
correlative analyses. Third, three C9orf72 mutation carriers had 
ALS without FTD, which, although increasingly recognised as 
part of the FTD spectrum,1 represents a clinically distinct pheno-
type. We ensured that these subjects did not affect our main 
results by repeating group comparisons after exclusion of these 
subjects. Finally, although brief medical and neurological history 
and examination did not reveal any significant neurological 
comorbidities, asymptomatic diseases, including cerebrovascular 
disease, could have confounded NPTX measurements. Future 
research focusing on potential confounding factors will be an 
important next step.
In conclusion, we provide evidence for NPTX2 as a novel CSF 
biomarker in genetic FTD. Its synaptic localisation and correla-
tion with disease progression indicates that NPTX2 decreases 
probably reflect synaptic dysfunction or loss, providing novel 
opportunities for in vivo monitoring of synaptic integrity in 
genetic FTD. Treatment strategies aimed at improving synaptic 
connectivity may benefit from the use of NPTX2 as a tool to 
select and monitor patients with neural circuit dysfunction. 
More longitudinal data on NPTXs in presymptomatic and symp-
tomatic mutation carriers might verify their value as (pre- )clin-
ical biomarkers.
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